ENGAGE-501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

被引：0
|
作者：
Younes, Anas [1 ]
Hernandez, Francisco [2 ,3 ]
Bociek, R. Gregory [4 ]
Kasamon, Yvette L. [5 ]
Lee, Peter [6 ]
Gore, Lia [7 ]
Buglio, Daniela [8 ]
Copeland, Amanda [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Clin Invest & Translat Res Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Immunol Canc Cell Ctr, Buffalo, NY 14263 USA
[4] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Tower Canc Res Fdn, Beverly Hills, CA USA
[7] Univ Colorado Canc Ctr, Aurora, CO USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[9] Univ Texas Houston, MD Anderson Canc Ctr Hymphoma Myeloma, Houston, TX USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1614 / 1615
页数：2
相关论文
共 50 条
  • [1] ENGAGE-501; Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) hi relapsed and refractory Hodgkin's lymphoma (HL)
    Younes, A.
    Rosen, P. J.
    Hernandez-Ilizaliturri, F. J.
    Bociek, G.
    Kasamon, Y. L.
    Copeland, A.
    Lee, G. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] ENGAGE-501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
    Batlevi, Connie Lee
    Kasamon, Yvette
    Bociek, R. Gregory
    Lee, Peter
    Gore, Lia
    Copeland, Amanda
    Sorensen, Rachel
    Ordentlich, Peter
    Cruickshank, Scott
    Kunkel, Lori
    Buglio, Daniela
    Hernandez-Ilizaliturri, Francisco
    Younes, Anas
    HAEMATOLOGICA, 2016, 101 (08) : 968 - 975
  • [3] The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study
    Younes, Anas
    Hernandez, Francisco
    Bociek, R. Gregory
    Kasamon, Yvette L.
    Lee, Peter
    Gore, Lia
    Copeland, Amanda R.
    BLOOD, 2011, 118 (21) : 1168 - 1168
  • [4] Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)
    Sermer, David J.
    Vardhana, Santosha
    Biggar, Erin
    Moskowitz, Alison J.
    Joffe, Erel
    Khan, Niloufer
    Straus, David J.
    Kumar, Anita
    Zelenetz, Andrew D.
    Horwitz, Steven M.
    Noy, Ariela
    Batlevi, Connie Lee
    Hamilton, Audrey
    Owens, Colette
    Matasar, Matthew J.
    Palomba, M. Lia
    Lee, Christina Y.
    Falchi, Lorenzo
    Johnson, William T.
    Schoder, Heiko
    Dogan, Ahmet
    Bunyaviroch, Tira
    Seshan, Venkatraman
    Salles, Gilles
    Younes, Anas
    Von Keudell, Gottfried
    BLOOD, 2021, 138
  • [5] Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).
    Sermer, David J.
    Vardhana, Santosha Adipudi
    Ames, Ashley
    Biggar, Erin
    Moskowitz, Alison J.
    Batlevi, Connie Lee
    Caron, Philip
    Hamilton, Audrey M.
    Moskowitz, Craig H.
    Matasar, Matthew J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    Von Keudell, Gottfried
    Yahalom, Joachim
    Rademaker, Jurgen
    Dogan, Ahmet
    Seshan, Venkatraman E.
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    Younes, Anas
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Bartlett, Nancy L.
    Cheson, Bruce D.
    de Vos, Sven
    Forero-Torres, Andres
    Moskowitz, Craig H.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Chen, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2183 - 2189
  • [7] Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT)
    Sureda, A.
    Engert, A.
    Browett, P. J.
    Radford, J. A.
    Verhoef, G. E.
    Ramchandren, R.
    Myke, N.
    Shen, A.
    Le Corre, C.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] RESULTS FROM A PHASE II STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN RELAPSED OR REFRACTORY INDOLENT NOW HODGKIN'S LYMPHOMA
    Peter, H. W.
    Vose, J. M.
    Moore, T. D.
    Reeder, C. B.
    Cole, C. E.
    Justice, G.
    Kaplan, H. P.
    Voralia, M.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J. B.
    Witzig, T. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 107 - 107
  • [9] ANALYSIS OF A PHASE 2 STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Dutia, M.
    DeRoock, I.
    Chee, K.
    O'Donnell, R.
    Quirch, C.
    Reed-Pease, C.
    Tuscano, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 118 - 118
  • [10] RESULTS FROM AN INTERNATIONAL STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE IN RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA
    Haioun, C.
    Reeder, C. B.
    Polikoff, J.
    Chowhan, N. M.
    Esseessee, I.
    Greenberg, R.
    Ervin-Haynes, A.
    Pietronigro, D.
    Zeldis, J. B.
    Witzig, T. E.
    Czuczman, M. S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 159 - 159
12345